Report Overview
In 2025, the Global Infant Formula Market was valued at USD 90.4 billion, and between 2026 and 2035, this market is estimated to register a CAGR of 8.7%, reaching about USD 207.1 billion by 2035. Asia Pacific held a dominant market position, capturing more than a 38.00% share, holding USD 34.4 billion in revenue.
The global infant formula industry occupies a critical position within the food and nutrition sector, serving as the primary alternative or supplement to breast milk for infants from birth through early childhood. As of 2024, nearly half (48%) of infants under six months were exclusively breastfed globally, according to the World Health Organization (WHO), bringing the world close to the 50% target set for 2025. This indicates that a large share of infants continue to follow feeding practices other than exclusive breastfeeding, including mixed feeding and, where appropriate, infant formula use.
- According to a joint statement by the UNICEF Executive Director and WHO Director General issued on 31 July 2024, improving breastfeeding rates could save more than 820,000 children’s lives each year. Infant formula therefore continues to play an important nutritional role for infants who cannot be exclusively breastfed because of medical, nutritional, or other circumstances.
Key Takeaways
- The global infant formula market was valued at USD 90.4 billion in 2025.
- The global market is projected to grow at a CAGR of 8.7% and is estimated to reach USD 207.1 billion by 2035.
- On the basis of product type, Standard Infant Formula dominated the market, constituting 52.00% of the total market share.
- Based on form, Powdered Formula dominated the infant formula market, with a substantial market share of 71.00%.
- Based on the distribution channel, Supermarkets & Hypermarkets led the market, accounting for 44.00% of the total market share.
- Based on the ingredient type, Cow Milk Based formula dominated the market, comprising 63.00% of the total market.
- Among the age groups, 0 -6 Months held the largest share in the infant formula market, accounting for 41.00% of the market.
- In 2025, Asia Pacific was the dominant regional market, accounting for 38.00% of the global infant formula market.
Multiple structural factors continue to support demand for infant formula worldwide. WHO states that undernutrition is associated with approximately 2.7 million child deaths annually, representing 45% of all child deaths, and emphasizes that the first 2 years of life are critical for healthy growth and development. Urbanization, changing family structures, and increasing participation of women in the workforce have influenced infant feeding practices in many countries. At the same time, greater parental awareness of infant nutrition has encouraged demand for scientifically formulated products, including specialty and age specific formulas designed to meet different nutritional needs during early childhood.
- At the 78th World Health Assembly, WHO Member States adopted a resolution to increase the global exclusive breastfeeding target from 50% to 60% by 2030. While breastfeeding remains the recommended standard, infant formula continues to serve as an essential nutritional option for infants who are not exclusively breastfed. WHO also estimates that approximately 4.5 billion people worldwide do not have full coverage of essential health services, highlighting continued challenges in access to maternal and child healthcare and breastfeeding support in many low and middle income countries.
On the regulatory front, governments and international organizations continue to strengthen oversight of infant formula safety and supply. The Codex Alimentarius Commission, jointly established by FAO and WHO, provides internationally recognized standards for the composition, safety, and labeling of infant formula that serve as the basis for many national regulations. In the United States, the U.S. Food and Drug Administration (FDA) released its Long Term National Strategy to Increase the Resiliency of the U.S. Infant Formula Market in January 2025.
By Product Type
Standard Infant Formula dominates with 52.00% share due to its wide acceptance as the primary nutrition choice for newborns.
In 2025, Standard Infant Formula held a dominant market position, capturing more than a 52.00% share of the global infant formula market. Its leading position was supported by its broad use as a substitute or supplement to breast milk when breastfeeding was not possible or insufficient. The segment continued to benefit from established nutritional standards set by food safety authorities, ensuring that products met essential infant dietary requirements.
The Follow on Formula (6-12 Months) segment emerged as the fastest growing category in 2025. Growth was supported by increasing awareness among parents about age specific nutrition during the complementary feeding stage. As infants transitioned from exclusive milk feeding to solid foods, follow on formulas remained an important part of balanced nutrition in many households. Food safety authorities continued to regulate the nutritional composition of follow on formulas to ensure they met the dietary needs of older infants.
By Form
Powdered Formula dominates with 71.00% share due to its longer shelf life and ease of storage.
In 2025, Powdered Formula held a dominant market position, capturing more than a 71.00% share of the global infant formula market. Its strong position was supported by its long shelf life, convenient storage, and lower transportation costs compared to liquid products. The format remained widely preferred by families because it could be prepared as needed and was available in a broad range of pack sizes. Food safety authorities continued to maintain strict manufacturing and labeling requirements for powdered infant formula to ensure product quality and nutritional consistency.
The Ready to Feed (RTF) segment was the fastest growing form in 2025. Growth was driven by increasing demand for convenient feeding solutions that require no mixing or preparation. This format became more popular among working parents, travelers, and healthcare facilities where ease of use and reduced preparation time were important. Food safety authorities continued to recognize ready to feed products as a sterile option before opening, making them suitable for specific feeding situations when handled according to recommended guidelines.
By Distribution Channel
Supermarkets & Hypermarkets dominate with 44.00% share due to their wide product availability and strong consumer accessibility.
In 2025, Supermarkets & Hypermarkets held a dominant market position, capturing more than a 44.00% share of the global infant formula market. Their leadership was supported by the availability of a wide range of infant formula brands, product formats, and age specific options under one roof, allowing parents to compare products before purchase. These retail outlets also maintained strong consumer trust by following food safety and storage requirements established by national food safety authorities, ensuring proper handling of infant nutrition products.
The Online Retail segment was the fastest growing distribution channel in 2025. Growth was driven by increasing consumer preference for convenient home delivery, wider product selection, and easy access to specialty infant formula products that may not always be available in physical stores. Parents increasingly used digital platforms to compare product information, ingredient details, and nutritional labels before making purchases.
By Ingredient Type
Cow Milk Based formula dominates with 63.00% share due to its established nutritional profile and broad consumer acceptance.
In 2025, Cow Milk Based held a dominant market position, capturing more than a 63.00% share of the global infant formula market. Its leading position was supported by its long standing use as the primary ingredient in infant formula products designed to meet established nutritional standards. Food safety authorities continued to regulate the composition of cow milk based infant formula to ensure that essential nutrients were provided in appropriate amounts for infant growth and development.
The Organic Formula segment was the fastest growing ingredient type in 2025. Growth was supported by rising consumer interest in products made with organically sourced ingredients and produced under certified organic farming practices. Parents increasingly preferred organic infant formula as awareness of ingredient transparency and clean label products continued to expand. Food safety authorities and certified organic regulatory bodies maintained strict standards for organic production, labeling, and ingredient sourcing, strengthening consumer confidence in these products.
By Age Group
0-6 Months dominates with 41.00% share as early life nutrition remains the primary focus for infant feeding.
In 2025, 0-6 Months held a dominant market position, capturing more than a 41.00% share of the global infant formula market. The segment maintained its leading position because this stage represents the most critical period of infant nutrition when formula is used as a substitute or supplement to breast milk if breastfeeding is not possible or appropriate. Food safety authorities continued to enforce strict nutritional and safety standards for infant formula intended for newborns and young infants, ensuring products met essential dietary requirements.
The 1-3 Years segment was the fastest growing age group in 2025. Growth was driven by increasing parental awareness of nutritional support during the toddler stage, when children experience rapid physical and cognitive development. Toddler formulas gained wider acceptance as parents looked for products containing essential vitamins and minerals to complement regular diets.
Key Market Segments
By Product Type
- Standard Infant Formula
- Follow on Formula (6-12 months)
- Growing up / Toddler Formula
- Specialty Formula (Hypoallergenic, Lactose free, etc.)
By Form
- Powdered Formula
- Liquid Concentrate
- Ready to Feed (RTF)
By Distribution Channel
- Supermarkets & Hypermarkets
- Pharmacies & Drug Stores
- Online Retail
- Specialty Stores
By Ingredient Type
- Cow Milk Based
- Soy Based
- Organic Formula
- Protein Hydrolysate / Specialty
By Age Group
- 0-6 Months
- 6-12 Months
- 1-3 Years
Driver Analysis
APAC Demographic Bifurcation: China’s Birth Collapse vs. India’s Growth Corridor
China recorded roughly 8.2 million births in 2025, the lowest tally in decades and less than half the 17.86-million peak registered in 2016, directly compressing the addressable infant cohort for formula manufacturers operating in what remains the single largest national market by formula spend. Because an estimated 60-70% of Chinese infants consume some formula by six months of age, this cohort contraction translates almost linearly into unit-volume attrition, forcing multinational players such as Nestlé to consolidate manufacturing footprints exemplified by the planned closure of a dedicated China-facing production plant by early 2026 with output shifted to Suzhou to defend margins against a shrinking base.
This dynamic is structurally deflationary for China-weighted revenue models, pushing incumbents toward premiumization and toward SKU rationalization rather than capacity expansion. Simultaneously, India’s baby-food and infant-formula segment, valued near USD 6.30 billion in 2025, is compounding at an estimated 4.5% CAGR into 2034 on the back of urbanization, rising dual-income households, and expanding organized retail penetration, partially offsetting APAC-wide demand erosion.
Drivers Impact Analysis
| Driver | (~) % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| APAC demographic bifurcation | -1.2% | China core (negative), APAC corridors: India, Indonesia, Vietnam (positive) | Long term (≥4 years) |
| US regulatory overhaul under Operation Stork Speed and nutrient-standard modernization | +1.8% | North America core | Medium term (2-4 years) |
| China tariff liberalization on retail-packaged infant formula | +1.1% | China core, EU/Oceania export corridors (NZ, Australia, Netherlands) | Short term (≤2 years) |
| HMO/HiMO ingredient premiumization and reformulation cycle | +2.0% | North America core, EU, APAC premium segment | Medium term (2-4 years) |
| Goat-milk and specialty-format | +1.5% | APAC core, EU, South America spill-over | Medium term (2-4 years) |
| India domestic formula demand growth via urbanization and rising female workforce participation | +0.9% | India, South Asia corridor | Long term (≥4 years) |
Restraint Analysis
China Birth-Cohort Decline
China’s birth cohort is now the most consequential volume restraint in global infant formula: official data reported roughly 7.9 million births in 2025, down 1.6 million year on year, or approximately 17%, with the birth rate declining to about 5.6 per 1,000 population; this leaves the 2025 cohort about 56% below the 2016 peak near 17.9 million and reduces the available first-year formula consumer pool before brand, price, or distribution factors are considered. For manufacturers, a 17% decline in newborns does not translate into an identical revenue decline because premiumization, follow-on formula, and toddler nutrition partly cushion value, but it creates severe fixed-cost absorption pressure in China-based blending, filling, canning, and quality-control assets where utilization falls faster than variable ingredient spend.
The resulting commercial effect is SKU rationalization, lower trade spend productivity, more promotional discounting, and weaker distributor inventory turns; the burden extends to New Zealand, Australian, Dutch, Irish, and other export suppliers whose China-oriented capacity was built around a materially larger birth cohort. China’s maintained 5% provisional tariff on standard retail infant formula may improve landed-cost competitiveness relative to the 15% standard MFN rate, but it cannot compensate for a structural contraction in the underlying infant base.
Restraint Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| China birth-cohort decline | -2.2% | China core, APAC exporters | Long term (≥4 years) |
| Formula safety recalls | -1.4% | North America, EU, APAC | Short term (≤2 years) |
| Regulatory reformulation burden | -1.1% | North America core, EU, China, India | Medium term (2-4 years) |
| Dairy-input and packaging volatility | -0.9% | Global; import-dependent APAC | Short term (≤2 years) |
| Low competition, high concentration | -0.8% | North America core | Medium term (2-4 years) |
| Affordability and marketing limits | -1.0% | India, Africa, South Asia, LATAM | Long term (≥4 years) |
Opportunity Analysis
Clinical Specialty-Formula Platforms
Specialty and medically indicated formulas represent an under-monetized adjacency rather than a baseline driver because most large portfolios still allocate their broadest distribution and R&D capacity to standard cow-milk powder, while high-complexity segments such as extensively hydrolyzed, amino-acid-based, metabolic-disorder, premature-infant, lactose-free, and thickened formulas remain supply constrained and commercially fragmented. A scaled producer can build a specialized platform around hospital neonatal intensive-care units, pediatric gastroenterology networks, pharmacies, and reimbursed channels, converting a single transactional purchase into a 6–18-month care pathway with materially higher retention and lower price elasticity; the revenue opportunity is amplified because specialty products can command two to five times the realized revenue per kilogram of conventional powder, although they require higher clinical-evidence, traceability, and manufacturing-validation costs.
The US FDA requires manufacturers introducing a new formula to register, notify, and submit compliance verification generally at least 90 days before interstate marketing, meaning early regulatory sequencing becomes a defensible first-mover advantage rather than administrative overhead. In China, special medical-purpose formula has preferential treatment versus ordinary retail formula in the tariff framework, with the 2025 provisional schedule listing a 0% rate for dairy-based infant formula for special medical purposes compared with 5% for standard retail formula, creating an import-cost wedge for qualified products. This is future upside because clinical platforms require targeted evidence generation, payer contracting, hospital education, and specialty manufacturing capability that are not uniformly embedded in mainstream category forecasts; successful execution can shift a manufacturer’s gross-margin mix upward by an estimated 300–700 basis points over a four-year portfolio cycle.
Opportunity Impact Analysis
| Opportunity | (~) % Potential CAGR | Geographic Relevance | Execution Window |
|---|---|---|---|
| Clinical specialty-formula platforms | +2.1% | North America, EU, China, GCC | Medium term (2-4 years) |
| HMO portfolio licensing | +1.7% | North America, EU, APAC premium | Medium term (2-4 years) |
| Subscription and D2C replenishment | +1.3% | North America, EU, urban APAC | Short term (≤2 years) |
| India value-tier localization | +1.5% | India, South Asia, Africa | Long term (≥4 years) |
| WIC and public-procurement reform | +1.2% | North America core | Medium term (2-4 years) |
| Regional M&A and co-manufacturing | +1.6% | APAC, EU, Latin America | Short term (≤2 years) |
Challenges Analysis
Fragile Supplier Networks
Infant formula supply chains continue to carry a systemic single-point-of-failure risk because manufacturers frequently operate short, just-in-time routes from specialized ingredient suppliers through a small number of blending, drying, filling, and retail-distribution nodes, leaving little buffer when a supplier, line, or laboratory hold disrupts production. Qualitative research on the 2022 US recall found that direct manufacturer-to-retailer distribution and low stockholding made delays at either ingredient allocation or manufacturing stages capable of turning quickly into retail shortages.
- This is no longer an isolated US problem: formula production incorporates at least 19 identifiable hazard points across its supply chain, while dairy proteins, lactose, specialty oils, vitamins, minerals, HMOs, can components, lids, and testing consumables often have different lead-time, qualification, and geography profiles.
The operating penalty is that dual sourcing is slow and expensive because each replacement ingredient must pass microbiological, nutritional, allergen, sensory, and stability validation; a manufacturer may need to carry 45–90 days of strategic inventory for selected high-risk inputs rather than 15–30 days of conventional stock, increasing working capital and expiry-management risk.
Challenges Impact Analysis
| Challenge | (~) % CAGR Friction | Geographic Relevance | Mitigation Horizon |
|---|---|---|---|
| Fragile supplier networks | -1.3% | North America, EU, APAC corridors | Medium term (2-4 years) |
| Contaminant-control escalation | -1.1% | North America core, EU, China | Medium term (2-4 years) |
| Local recipe registration | -0.8% | China core, APAC import markets | Medium term (2-4 years) |
| Specialist workforce scarcity | -0.7% | North America, EU, APAC plants | Long term (≥4 years) |
| Sustainable-packaging transition | -0.6% | EU regulatory hubs, global exporters | Medium term (2-4 years) |
| Precision-fermentation scale-up | -0.9% | North America, EU, APAC premium | Long term (≥4 years) |
Geopolitical Impact Analysis
Ongoing Geopolitical Conflicts Reinforce the Need for Resilient Infant Formula Supply Chains.
The ongoing Russia Ukraine war and instability across the Middle East continue to affect the global infant formula market by increasing pressure on international logistics, energy costs, and cross border trade. Infant formula manufacturers depend on globally sourced dairy ingredients, vegetable oils, vitamins, minerals, and packaging materials, making supply chains vulnerable to geopolitical
- In January 2025, the U.S. Food and Drug Administration (FDA) released its Long Term National Strategy to Increase the Resiliency of the U.S. Infant Formula Market, building on actions introduced after the February 2022 infant formula shortage. The strategy focuses on improving supply chain resilience, preventing contamination, supporting new market entrants, and improving visibility into supply chain risks and shortages.
Recent events have further highlighted the importance of resilient supply chains. In July 2026, the FDA urged infant formula manufacturers to strengthen oversight of ingredient suppliers following safety incidents linked to powdered infant formula. The agency stated that the 2025 ByHeart outbreak was the first confirmed U.S. infant botulism outbreak linked to infant formula in nearly 50 years, while a separate global contamination event during late 2025 through early 2026 resulted in nearly 150 suspected and confirmed cases of cereulide intoxication across 10 countries.
Regional Analysis
Asia Pacific dominated the infant formula market with a 38.00% share, valued at US$ 34.4 Billion, supported by high birth volumes and expanding infant nutrition demand.
In 2025, Asia Pacific held a dominant position in the global infant formula market, accounting for 38.00% of the total market and reaching a value of US$ 34.4 billion. The region’s leadership was supported by its large infant population, rising disposable incomes, expanding urbanization, and growing awareness of infant nutrition. Countries such as China, India, Indonesia, and Vietnam continued to represent major demand centers due to their high annual birth rates and improving access to organized retail and healthcare services.
- According to the World Health Organization, nearly 48% of infants under six months were exclusively breastfed globally in 2024, indicating that a large share of infants continue to follow feeding practices other than exclusive breastfeeding, including mixed feeding and, where appropriate, infant formula use. Across Asia Pacific, breastfeeding practices vary considerably, supporting continued demand for regulated infant nutrition products.
The OECD and WHO’s Health at a Glance: Asia Pacific 2024 report shows that several countries in the region have already achieved the 50% exclusive breastfeeding target, while countries such as China and Thailand remain below 40%, reflecting significant variation in infant feeding practices. Governments across Asia Pacific have also strengthened food safety regulations by aligning national standards with the Codex Alimentarius guidelines for infant formula composition and labeling.
Key Regions and Countries Covered
- North America
- The US
- Canada
- Europe
- Germany
- France
- The UK
- Spain
- Italy
- Russia & CIS
- Rest of Europe
- APAC
- China
- Japan
- South Korea
- India
- ASEAN
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of MEA
Key Players Analysis
The infant formula market is highly competitive, with leading companies such as Nestlé S.A., Danone S.A., Abbott Laboratories, Mead Johnson (Reckitt), FrieslandCampina, Arla Foods, HiPP GmbH, Perrigo Company plc, Yili Group, China Feihe Limited, Synutra International, Royal DSM Firmenich, Bellamy’s Organic, Kraft Heinz (Nurture Inc.), and Beingmate Baby & Child Food focusing on nutrition science, product quality, and regulatory compliance to strengthen their market positions.
A key strategy is continuous investment in research and development to introduce formulas containing human milk oligosaccharides, probiotics, prebiotics, omega 3 fatty acids, and specialized protein blends that support infant growth and development. Companies are also expanding premium and specialty product portfolios, including organic, lactose free, hypoallergenic, and hydrolyzed formulas, to meet changing consumer preferences and address specific nutritional requirements across different age groups.
Manufacturers continue to strengthen production capacity, supply chain resilience, and geographic presence to meet rising global demand. Strategic investments in advanced manufacturing facilities, quality assurance systems, and ingredient traceability help maintain product safety while complying with strict food safety regulations across international markets. Companies are also expanding their presence in high growth regions, particularly across Asia Pacific, through local production, distribution partnerships, and wider retail coverage.
Market Key Players
- Nestlé S.A.
- Danone S.A.
- Abbott Laboratories
- Mead Johnson (Reckitt)
- FrieslandCampina
- Arla Foods
- HiPP GmbH
- Perrigo Company plc
- Yili Group
- China Feihe Limited
- Synutra International
- Royal DSM Firmenich
- Bellamy’s Organic
- Kraft Heinz (Nurture Inc.)
- Beingmate Baby & Child Food
Key Development
- January 2026: Abbott Laboratories reported its fourth-quarter and full-year 2025 results, with worldwide Nutrition sales of 451 billion US dollars for the year, up 0.4% on a reported basis and 1.2% on an organic basis, with international pediatric nutrition sales growing 3.7% organically for the year even as US pediatric nutrition sales declined.
- March 2026: Reckitt Benckiser Group reported its results for the year ended 31 December 2025, with its Mead Johnson Nutrition business posting like for like net revenue growth of 8% to 2,119 million British pounds, driven by premiumisation and speciality brand growth as its North America business recovered from a 2024 tornado-related warehouse disruption, with adjusted operating profit up 8.5% to 433 million British pounds.
- May 2026: Perrigo Company reported first-quarter 2026 financial results, with its Infant Formula segment posting net sales growth of 1% to 89.7 million US dollars, driven by growth in contract infant formula, even as the company’s total consolidated net sales declined 7.2% for the quarter.
Report Scope
| Report Features | Description |
|---|---|
| Market Value (2025) | USD 90.4 Bn |
| Forecast Revenue (2035) | USD 207.1 Bn |
| CAGR (2026 2035) | 8.7% |
| Base Year for Estimation | 2025 |
| Historic Period | 2020 2024 |
| Forecast Period | 2026 2035 |
| Report Coverage | Revenue Forecast, Market Dynamics, Competitive Landscape, Recent Developments |
| Segments Covered | By Product Type (Standard Infant Formula, Follow on Formula (6-12 Months),Growing up/Toddler Formula, Specialty Formula (Hypoallergenic, Lactose free, etc.)), By Form (Powdered Formula, Liquid Concentrate, Ready to Feed (RTF)), By Distribution Channel (Supermarkets & Hypermarkets, Pharmacies & Drug Stores, Online Retail, Specialty Stores), By Ingredient Type (Cow Milk Based, Soy Based, Organic Formula, Protein Hydrolysate / Specialty), By Age Group (0-6 Months, 6-12 Months, 1-3 Years). |
| Regional Analysis | North America – The US & Canada; Europe – Germany, France, The UK, Spain, Italy, Russia & CIS, Rest of Europe; APAC China, Japan, South Korea, India, ASEAN & Rest of APAC; Latin America Brazil, Mexico & Rest of Latin America; Middle East & Africa GCC, South Africa, & Rest of MEA |
| Competitive Landscape | Nestlé S.A., Danone S.A., Abbott Laboratories, Mead Johnson (Reckitt), FrieslandCampina, Arla Foods, HiPP GmbH, Perrigo Company plc, Yili Group, China Feihe Limited, Synutra International, Royal DSM Firmenich, Bellamy’s Organic, Kraft Heinz (Nurture Inc.), and Beingmate Baby & Child Food. |
| Customization Scope | Customization for segments, region/country level will be provided. Moreover, additional customization can be done based on the requirements. |
| Purchase Options | We have three licenses to opt for: Single User License, Multi User License (Up to 5 Users), Corporate Use License (Unlimited Users and Printable PDF) |
